440 related articles for article (PubMed ID: 35578182)
41. Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real-world data from a Greek registry.
Argyriou AA; Dermitzakis EV; Xiromerisiou G; Rallis D; Soldatos P; Litsardopoulos P; Vikelis M
Eur J Neurol; 2023 May; 30(5):1435-1442. PubMed ID: 36773011
[TBL] [Abstract][Full Text] [Related]
42. Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials.
Silberstein SD; McAllister P; Ning X; Faulhaber N; Lang N; Yeung P; Schiemann J; Aycardi E; Cohen JM; Janka L; Yang R
Headache; 2019 Jun; 59(6):880-890. PubMed ID: 30977520
[TBL] [Abstract][Full Text] [Related]
43. Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study.
Caponnetto V; Russo A; Silvestro M; Tessitore A; De Icco R; Vaghi G; Sances G; Tassorelli C; Baraldi C; Castro FL; Guerzoni S; Prudenzano MP; Fallacara A; Gentile M; Ornello R; Onofri A; Burgalassi A; Chiarugi A; De Cesaris F; Granato A; Casalena A; De Tommaso M; Mampreso E; Merlo P; Coppola G; Battistini S; Rebecchi V; Rainero I; Sepe FN; Dalla Volta G; Sacco S; Geppetti P; Iannone LF;
CNS Drugs; 2023 Dec; 37(12):1069-1080. PubMed ID: 37999868
[TBL] [Abstract][Full Text] [Related]
44. Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine.
Brandes JL; Kudrow D; Yeung PP; Sakai F; Aycardi E; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y
Cephalalgia; 2020 Apr; 40(5):470-477. PubMed ID: 31752521
[TBL] [Abstract][Full Text] [Related]
45. Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study.
Ashina M; Mitsikostas DD; Amin FM; Kokturk P; Schankin CJ; Sahin G; Pozo-Rosich P; Dorman PJ; Nežádal T; Poole AC; Martins IP; Sumelahti ML; Ramirez Campos V; Ahn AH; Lyras L; Tassorelli C
Cephalalgia; 2023 Nov; 43(11):3331024231214987. PubMed ID: 37987641
[TBL] [Abstract][Full Text] [Related]
46. Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway.
Waliszewska-Prosół M; Martelletti P
Dent Med Probl; 2024; 61(1):9-11. PubMed ID: 38284301
[TBL] [Abstract][Full Text] [Related]
47. Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines.
Cohen JM; Dodick DW; Yang R; Newman LC; Li T; Aycardi E; Bigal ME
Headache; 2017 Oct; 57(9):1375-1384. PubMed ID: 28862758
[TBL] [Abstract][Full Text] [Related]
48. Fremanezumab for the preventive treatment of migraine.
Silberstein SD; Cohen JM; Yeung PP
Expert Opin Biol Ther; 2019 Aug; 19(8):763-771. PubMed ID: 31177856
[No Abstract] [Full Text] [Related]
49. Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study.
Lipton RB; Cohen JM; Galic M; Seminerio MJ; Yeung PP; Aycardi E; Bigal ME; Bibeau K; Buse DC
Headache; 2021 Apr; 61(4):662-672. PubMed ID: 33891348
[TBL] [Abstract][Full Text] [Related]
50. Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE.
Alsaadi T; Noori S; Varakian R; Youssef S; Almadani A
BMC Neurol; 2022 Jun; 22(1):221. PubMed ID: 35710354
[TBL] [Abstract][Full Text] [Related]
51. Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine.
Winner PK; Spierings ELH; Yeung PP; Aycardi E; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y
Headache; 2019 Nov; 59(10):1743-1752. PubMed ID: 31675102
[TBL] [Abstract][Full Text] [Related]
52. Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy Responses.
Fiedler-Kelly J; Passarell J; Ludwig E; Levi M; Cohen-Barak O
Headache; 2020 Jul; 60(7):1376-1391. PubMed ID: 32445498
[TBL] [Abstract][Full Text] [Related]
53. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
54. Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients.
Curone M; Tullo V; Didier HA; Bussone G
Neurol Sci; 2022 Sep; 43(9):5759-5761. PubMed ID: 35836032
[TBL] [Abstract][Full Text] [Related]
55. Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study.
Lipton RB; Cohen JM; Bibeau K; Galic M; Seminerio MJ; Ramirez Campos V; Halker Singh RB; Ailani J
Headache; 2020 Nov; 60(10):2444-2453. PubMed ID: 33179323
[TBL] [Abstract][Full Text] [Related]
56. Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study.
Spierings ELH; Ning X; Ramirez Campos V; Cohen JM; Barash S; Buse DC
Headache; 2021 Oct; 61(9):1376-1386. PubMed ID: 34374086
[TBL] [Abstract][Full Text] [Related]
57. No "Wearing-Off Effect" Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long-Term Study.
Blumenfeld AM; Stevanovic DM; Ortega M; Cohen JM; Seminerio MJ; Yang R; Jiang B; Tepper SJ
Headache; 2020 Nov; 60(10):2431-2443. PubMed ID: 33009665
[TBL] [Abstract][Full Text] [Related]
58. Early Effect of Calcitonin Gene-related Peptide Monoclonal Antibodies in Migraine with Medication Overuse: A Single-center Retrospective Study.
Ito Y; Mitsufuji T; Okada M; Fujita S; Yokoyama R; Kawasaki H; Yamamoto T
Intern Med; 2023 Dec; 62(23):3455-3460. PubMed ID: 37062749
[TBL] [Abstract][Full Text] [Related]
59. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.
Zhu Y; Liu Y; Zhao J; Han Q; Liu L; Shen X
Neurol Sci; 2018 Dec; 39(12):2097-2106. PubMed ID: 30182284
[TBL] [Abstract][Full Text] [Related]
60. Fremanezumab in the treatment of migraines: evidence to date.
Robblee J; VanderPluym J
J Pain Res; 2019; 12():2589-2595. PubMed ID: 31686900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
